Cholesteryl Ester Transfer Protein and ATP-Binding Cassette Transporter A1 Genotype Alter the Atorvastatin and Simvastatin Efficacy: Time for Genotype-Guided Therapy
Kolovou G – The TaqIB and R219K (opposite to I405V) gene polymorphisms seem to modify the response to lipid–lowering therapy with simvastatin or atorvastatin treatment.
The authors compared the efficacy of atorvastatin with simvastatin according to cholesteryl ester transfer protein (CETP) and adenosine triphosphate–binding cassette transporter A1 (ABCA1) genes.
Patients treated with atorvastatin (n = 254) or simvastatin (n = 332) were genotyped for CETP (TaqIB and I405V) and ABCA1 (R219K) genetic variants.
For genotype B1B2, atorvastatin compared with simvastatin treatment resulted in a greater decrease in total cholesterol (35.4% vs 31.6%, P = .035) and a lower increase in high–density lipoprotein cholesterol (2% vs 8%, P = .05).
For genotype B2B2, atorvastatin compared with simvastatin treatment resulted in a lower decrease in low–density lipoprotein cholesterol (31.85 vs 42%, P = .029).
For genotypes RR and KK, atorvastatin compared with simvastatin treatment resulted in a greater decrease of triglycerides (27% vs 17% and 35% vs 15%, respectively; P = .02 for all comparisons).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.